Warner Lambert Co – ‘10-K405/A’ for 12/31/98 – EX-99

As of:  Monday, 4/19/99   ·   For:  12/31/98   ·   Accession #:  950117-99-792   ·   File #:  1-03608

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Amendment to Annual Report — [x] Reg. S-K Item 405   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K405/A   Warner-Lambert Company 10-K405/A                      23    132K 
 2: EX-3        Exhibit 3B                                            24     67K 
 3: EX-10       Exhibit 10(I)                                         44     80K 
 4: EX-12       Statement re: Computation of Ratios                    1      8K 
 5: EX-13       Annual or Quarterly Report to Security Holders        44±   184K 
 6: EX-21       Subsidiaries of the Registrant                         5±    34K 
 7: EX-23       Consent of Experts or Counsel                          1      7K 
 8: EX-27       Art. 5 FDS 1998 10-K/A                                 1      9K 
 9: EX-99       Exhibit 99(A)                                          2±     8K 

EX-99   —   Exhibit 99(A)

EX-99
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
                                                                   EXHIBIT 99(a)

CAUTIONARY STATEMENTS RELATING TO 'SAFE HARBOR' PROVISIONS OF THE 
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

  Certain Company communications contain forward-looking statements. These
statements may be identified by the use of forward-looking words or phrases such
as 'believe,' 'expect,' 'anticipate,' 'should,' 'planned,' 'may,' 'estimated'   
and 'potential.' These forward-looking statements are based on the Company's    
current expectations. The Private Securities Litigation Reform Act of 1995      
provides a 'safe harbor' for such forward-looking statements. In order to comply
with the terms of the safe harbor, the Company notes that a variety of factors  
could cause actual results and experience to differ materially from the         
anticipated results or other expectations expressed in such forward-looking     
statements. The risks and uncertainties that may affect the operations,         
performance, development and results of the Company's business include:         

         Changes in the favorable market reaction to the Company's significant
     pharmaceutical products, such as the cholesterol-lowering agent LIPITOR and
the type 2 diabetes drug REZULIN.                                     

   Competitive factors, including managed care and other groups or
  institutions seeking price discounts; technological advances attained by
competitors; and patents granted to or contested by competitors, which
would result in their ability to compete against the Company more     
effectively.                                                          

 Difficulties or delays in pharmaceutical product development,
including, but not limited to, the inability to identify viable new   
chemical compounds, to successfully complete toxicology testing and/or
     clinical trials, to obtain regulatory approval for the compounds or to gain
market acceptance of approved products.                               

  Unexpected safety or efficacy concerns arising with respect to
marketed products, whether or not scientifically justified, leading to
product recalls, withdrawals or other actions which could result in   
declining sales.                                                      

        The expiration of patents or governmental grants of exclusivity with
respect to the Company's products.                                    

        Government laws and regulations affecting domestic and international
operations, which could include matters affecting drug approval and   
    pricing; or actions of regulatory agencies with respect to products and/or
     manufacturing facilities which could result in fines, product interruptions
or withdrawals, plant closures or consent decrees.                    

       Changes in economic conditions (including inflation, interest rates
   and foreign currency exchange rates) in the global marketplace, including
     Canada, Japan, Mexico and Western Europe, where the Company has significant
businesses.                                                           

Significant litigation adverse to the Company, including,   
     particularly, product liability litigation, antitrust litigation and patent
and trademark litigation.